Latest Bubs Australia (Asx:Bub) News

Bubs Australia Limited reported a solid FY25 with $102.5 million revenue and outlined ambitious FY26 guidance targeting up to $125 million, driven by overseas markets and strategic investments.

Bubs Australia Limited announces it expects to recover A$825,000 from Willis Trading Limited’s secured creditor following arbitration proceedings, while no further recoveries are anticipated from related parties.

Bubs Australia reported a 30% increase in net revenue to $25.6 million for Q1 FY26, driven by robust US sales and a return to profitability with positive EBITDA. Despite inventory challenges in other regions, the company maintains a solid cash position and anticipates FDA approval by year-end.

Bubs Australia has appointed Paul Jensen as its new Independent Chair and Joe Coote as Managing Director and CEO, signaling a fresh leadership chapter for the infant formula and dairy company.

Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.

Bubs Australia has appointed Joe Coote as its new CEO, bringing extensive international FMCG and dairy leadership to spearhead its global growth ambitions in infant nutrition.

Bubs Australia Limited reports a strong FY25 with 29% revenue growth to $102.5 million, positive EBITDA turnaround, and sustained cash flow improvements. The company also advances its US market ambitions with a key FDA submission underway.

Bubs Australia has submitted critical clinical trial data to the US FDA, marking a pivotal step toward permanent approval for its infant formulas in the US market.

Bubs Australia has triumphed in a long-standing legal dispute, winning $26.5 million in arbitration awards against Alpha Group subsidiaries Alice Trading and Willis Trading. The company now faces the challenge of recovering the awarded sums.

Bubs Australia has reported a strong Q2 FY25 performance with a positive EBITDA turnaround and robust revenue growth, while advancing its critical FDA clinical trial in the US.